Foghorn Therapeutics (FHTX) Change in Account Payables (2019 - 2026)
Foghorn Therapeutics (FHTX) recorded quarterly Change in Account Payables of -$990000.0 in Q1 2026, down 193.93% quarter-over-quarter from $1.1 million in Q4 2025, and down 448.59% on a YoY basis from $284000.0 in Q1 2025.
Foghorn Therapeutics (FHTX) Change in Account Payables (2019 - 2026) Analysis & Trends
Foghorn Therapeutics' Change in Account Payables history runs 8 years deep, the most recent figure standing at -$990000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables fell 448.59% year-over-year to -$990000.0; the TTM figure through Mar 2026 stood at -$793000.0 (up 49.23% YoY), while the FY2025 annual figure was $481000.0, up 119.43% from the prior year.
- Change in Account Payables was -$990000.0 for Q1 2026 at Foghorn Therapeutics, down from $1.1 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $1.7 million in Q1 2023 to a low of -$1.4 million in Q2 2022.
- Historically, Change in Account Payables has averaged -$30823.5 across 5 years, with a median of -$171000.0 in 2023.
- The sharpest annual moves came in 2022 and 2026: Change in Account Payables jumped 847.62% in 2022, then sank 448.59% in 2026.
- A 5-year view of Change in Account Payables shows it stood at $157000.0 in 2022, then sank by 250.32% to -$236000.0 in 2023, then surged by 241.53% to $334000.0 in 2024, then soared by 215.57% to $1.1 million in 2025, then tumbled by 193.93% to -$990000.0 in 2026.
- The last three Change in Account Payables figures came in at -$990000.0 (Q1 2026), $1.1 million (Q4 2025), and -$110000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Foghorn Therapeutics | 282.33 Mn | 193.42 Mn | - | -990,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -990,000.00 |
| Mar 31, 2026 | -990,000.00 |
| Dec 31, 2025 | 1.05 Mn |
| Dec 31, 2025 | 1.05 Mn |
| Sep 30, 2025 | -110,000.00 |
| Sep 30, 2025 | -110,000.00 |
| Jun 30, 2025 | -747,000.00 |
| Jun 30, 2025 | -747,000.00 |
| Mar 31, 2025 | 284,000.00 |
| Mar 31, 2025 | 284,000.00 |
| Dec 31, 2024 | 334,000.00 |
| Dec 31, 2024 | 334,000.00 |
| Sep 30, 2024 | -1.35 Mn |
| Sep 30, 2024 | -1.35 Mn |
| Jun 30, 2024 | -829,000.00 |
| Jun 30, 2024 | -829,000.00 |
| Mar 31, 2024 | -629,000.00 |
| Mar 31, 2024 | -629,000.00 |
| Dec 31, 2023 | -236,000.00 |
| Dec 31, 2023 | -236,000.00 |